Cargando…

Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity

BACKGROUND: Ursodeoxycholic acid (UDCA) is used to treat primary biliary cirrhosis, intrahepatic cholestasis, and other cholestatic conditions. Although much has been learned about the molecular basis of the disease pathophysiology, our understanding of the effects of UDCA remains unclear. Possibly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buryova, Halka, Chalupsky, Karel, Zbodakova, Olga, Kanchev, Ivan, Jirouskova, Marketa, Gregor, Martin, Sedlacek, Radislav
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3835136/ https://www.ncbi.nlm.nih.gov/pubmed/24172289 http://dx.doi.org/10.1186/1471-230X-13-155

Ejemplares similares

ADAM10 and ADAM17 regulate EGFR, c-Met and TNF RI signalling in liver regeneration and fibrosis
por: Zbodakova, Olga, et al.
Publicado: (2021)

Hepatoprotective Effect of MMP-19 Deficiency in a Mouse Model of Chronic Liver Fibrosis
por: Jirouskova, Marketa, et al.
Publicado: (2012)

KLK5 and KLK7 Ablation Fully Rescues Lethality of Netherton Syndrome-Like Phenotype
por: Kasparek, Petr, et al.
Publicado: (2017)

A disintegrin and metalloprotease 10 (ADAM10) is a central regulator of murine liver tissue homeostasis
por: Müller, Miryam, et al.
Publicado: (2016)

The iRhom2/ADAM17 Axis Attenuates Bacterial Uptake by Phagocytes in a Cell Autonomous Manner
por: Seifert, Anke, et al.
Publicado: (2020)

NADPH oxidases and HIF1 promote cardiac dysfunction and pulmonary hypertension in response to glucocorticoid excess
por: Kračun, Damir, et al.
Publicado: (2020)

The iRhom homology domain is indispensable for ADAM17-mediated TNFα and EGF receptor ligand release
por: Düsterhöft, Stefan, et al.
Publicado: (2021)

A structural model of the iRhom–ADAM17 sheddase complex reveals functional insights into its trafficking and activity
por: Kahveci-Türköz, Selcan, et al.
Publicado: (2023)

Protective effect of ursodeoxycholic acid on COVID-19 in patients with chronic liver disease
por: Li, Yanyan, et al.
Publicado: (2023)

ADAM 17 endopeptidase
Publicado: (2009)

ADAM10 and ADAM17: New Players in Trastuzumab Resistance
por: Duffy, Michael J., et al.
Publicado: (2014)

ADAM10 and ADAM17—Novel Players in Retinoblastoma Carcinogenesis
por: Van Meenen, Dario, et al.
Publicado: (2022)

ADAM10 mediates shedding of carbonic anhydrase IX ectodomain non-redundantly to ADAM17
por: Zatovicova, Miriam, et al.
Publicado: (2022)

Cleavage Site Localization Differentially Controls Interleukin-6 Receptor Proteolysis by ADAM10 and ADAM17
por: Riethmueller, Steffen, et al.
Publicado: (2016)

Comparing the Protective Effects of Curcumin and Ursodeoxycholic Acid after Ethanol-Induced Hepatotoxicity in Rat Liver
por: Farashbandi, Azam Letafat, et al.
Publicado: (2021)

Exosome-Derived ADAM17 Promotes Liver Metastasis in Colorectal Cancer
por: Sun, Jinbing, et al.
Publicado: (2021)

Role of ADAM10 and ADAM17 in Regulating CD137 Function
por: Seidel, Jana, et al.
Publicado: (2021)

LRP1 shedding in human brain: roles of ADAM10 and ADAM17
por: Liu, Qiang, et al.
Publicado: (2009)

Upregulation of APP, ADAM10 and ADAM17 in the Denervated Mouse Dentate Gyrus
por: Del Turco, Domenico, et al.
Publicado: (2014)

Influence of Anoctamin-4 and -9 on ADAM10 and ADAM17 Sheddase Function
por: Leitzke, Sinje, et al.
Publicado: (2022)

Role of ADAM10 and ADAM17 in the Regulation of Keratinocyte Adhesion in Pemphigus Vulgaris
por: Kugelmann, Daniela, et al.
Publicado: (2022)

Regulation of A disintegrin and metalloproteinase (ADAM) family sheddases ADAM10 and ADAM17: The emerging role of tetraspanins and rhomboids
por: Matthews, Alexandra L., et al.
Publicado: (2017)

Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands
por: Sahin, Umut, et al.
Publicado: (2004)

Differential Surface Expression of ADAM10 and ADAM17 on Human T Lymphocytes and Tumor Cells
por: Ebsen, Henriette, et al.
Publicado: (2013)

The disintegrin-metalloproteinases ADAM10 and ADAM17 are upregulated in cutaneous squamous cell carcinomas
por: Oh, S.-T., et al.
Publicado: (2016)

ADAM10 and ADAM17 as Biomarkers Linked to Inflammation, Metabolic Disorders and Colorectal Cancer
por: Sikora-Skrabaka, Magdalena, et al.
Publicado: (2022)

ADAM10 and ADAM17, Major Regulators of Chronic Kidney Disease Induced Atherosclerosis?
por: Maas, Sanne L., et al.
Publicado: (2023)

Exploring the Potential Role of ADAM 17 and ADAM 22 in the Etiology of Autism Spectrum Disorders
por: Al-Mazidi, Sarah H., et al.
Publicado: (2023)

Epidermal ADAM17 is dispensable for Notch activation
por: Groot, Arjan J., et al.
Publicado: (2013)

Biological synthesis of ursodeoxycholic acid
por: Song, Peng, et al.
Publicado: (2023)

Metalloproteinases ADAM10 and ADAM17 Mediate Migration and Differentiation in Glioblastoma Sphere-Forming Cells
por: Siney, Elodie J., et al.
Publicado: (2016)

Analysis of the Conditions That Affect the Selective Processing of Endogenous Notch1 by ADAM10 and ADAM17
por: Alabi, Rolake O., et al.
Publicado: (2021)

Assessment of ADAM17 and ADAM10 proteins with CXCL10 and thyroid autoimmunity in vitiligo pathogenesis
por: Kılıc, Sevilay, et al.
Publicado: (2022)

Preferred SH3 Domain Partners of ADAM Metalloproteases Include Shared and ADAM-Specific SH3 Interactions
por: Kleino, Iivari, et al.
Publicado: (2015)

Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease
por: Caballero‐Camino, Francisco J., et al.
Publicado: (2020)

Both Specific Endothelial and Proximal Tubular Adam17 Deletion Protect against Diabetic Nephropathy
por: Palau, Vanesa, et al.
Publicado: (2021)

Ursodeoxycholic acid protects against lung injury induced by fat embolism syndrome
por: Niu, Fangfang, et al.
Publicado: (2020)

Effect of Ursodeoxycholic Acid Alone and Ursodeoxycholic Acid Plus Domperidone on Radiolucent Gallstones and Gallbladder Contractility in Humans
por: Tuncer, Ilyas, et al.
Publicado: (2012)

Ursodeoxycholic Acid in Treatment of Non-cholestatic Liver Diseases: A Systematic Review
por: Reardon, Jillian, et al.
Publicado: (2016)

Risk Factors of Glecaprevir/Pibrentasvir-Induced Liver Injury and Efficacy of Ursodeoxycholic Acid
por: Tamai, Hideyuki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qfrgnojs019pmrq03miiu6h588